Press Releases

The immune system actually wants to fight SARS-CoV-2 with antiviral signaling molecules. But a research team from Charité and MDC has now shown how such a signaling molecule can promote the replication of the virus. The results have been published in the journal EMBO Molecular Medicine.

February 11 marks the International Day of Women and Girls in Science. The Berlin Institute of Health (BIH ) and the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) are hosting a joint virtual event that will feature a film screening, a keynote lecture and a panel discussion. We want to examine and discuss what changes are needed to make science more diverse, equitable and inclusive.

A year ago, BIH , MDC and Charité launched the joint research focus "Single Cell Approaches for Personalised Medicine". Its aim is to use innovative single cell technologies to answer clinical questions. This aspiration will be put into practice by four new junior research groups, which have now started.

On January 1, 2021, the Berlin Institute of Health (BIH ) has become the translational research unit of Charité – Universitätsmedizin Berlin and will then form – alongside the hospital and the medical faculty – Charité’s third pillar.

The European Research Council (ERC) awarded Dr. Mina Gouti a €2.8 million Consolidator Grant to further develop miniature neuromuscular organoids for studying neuromuscular development and diseases. It was the second honor in as many weeks; she was also named an EMBO Young Investigator for her work.

PhD candidates now have the opportunity to apply for two new training programs. The EU is supporting the program for talented early-stage researchers at the MDC and other European research institutions to the tune of €4 million per network.

Berlin will become one of four new National Center for Tumor Diseases (NCT) locations in addition to Heidelberg and Dresden. This was announced today by the Federal Ministry of Education and Research, recognizing the outstanding achievements of Charité, the BIH and the MDC in advancing cancer treatment and research.

Hundreds of researchers, clinicians, industry leaders and policy makers from all around Europe are united by a vision of how to revolutionize healthcare. In a perspective in Nature and the LifeTime Strategic Research Agenda they now present a roadmap of how to leverage the latest scientific breakthroughs and technologies over the next decade, to track, understand and treat human cells throughout an individual’s lifetime.

Two MDC scientists – Kathrin de Rosa and Ilaria Piazza – have earned ERC Starting Grants to fuel their pioneering research. They are seeking answers to questions that may one day change the way we approach vaccines and think about how small molecules influence gene expression and disease.

MDC researchers received a $150,000 pilot project grant from the Chan Zuckerberg Initiative’s Neurodegeneration Challenge Network to investigate a defining feature of amyotrophic lateral sclerosis (ALS).